Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in moderate to severe active ulcerative colitis
2016-000420-26Phase 2Terminated
- Sponsor
- UCB
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Bimekizumab with Placebo (2 arms). Primary endpoint: Proportion of participants with clinical response per Mayo score at Week 8. Started Jul 2016; status: terminated.
02
Drugs
bimekizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-000420-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000420-26.